Hadassah

Placental Stem Cell Therapy to Treat Acute Radiation Syndrome Receives Boost from FDA

Tuesday, Oct 24 2017

Prof. Raphael Gorodetsky

In collaboration with Pluristem Therapeutics, the Hadassah Medical Organization developed a stem cell product from the human placenta to prevent and treat acute radiation syndrome (ARS). The product, PLX-R18, has just received orphan drug status from the U.S. Food and Drug Administration (FDA).

“Receiving orphan drug designation brings us one step closer to providing a next-generation medical countermeasure against ARS,” notes Zami Aberman, Co-Chief Executive Officer and Chairman of Pluristem.

As Pluristem explains: The designation involves close guidance by the FDA, which may accelerate the path to potential marketing approval; orphan drug grants; tax credits; and seven-year market exclusivity upon marketing approval.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery). PLX therapy holds promise as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy.

The earlier, less effective version of PLX cell therapy was tested initially at Hadassah on terminally ill patients who had no other treatment option. The results were “very good,” reports Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory in Hadassah’s Sharett Institute of Oncology.

Pluristem recently reported positive data from non-human primate studies of PLX-R18 treatment for ARS. Conducted by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH), the study revealed improvement in survival rates and the enhancement of recovery across all three major blood lineages: white blood cells, red blood cells, and platelets.

Pluristem reports also that PLX-R18 cells are being studied by the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute to examine the effectiveness of the cells as a treatment for ARS prior to, and within the first 24 hours of, exposure to radiation. Pluristem PLX-R18 cells are also being studied by Fukushima Medical University in Japan for the treatment of ARS and as an adjunct to radiotherapy in cancer patients.

A clinical trial at Hadassah with PLX-R18 is now in the planning stages, Prof. Gorodetsky relates. 

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 14 2018

A Hassidic Mother’s Promise to Donate a Kidney: Mission Accomplished

A young girl named Esti had a best friend named Tali whose father had kidney disease. He passed away before a kidney transplant could save his life.

READ MORE ›
alt_text

Friday, Nov 9 2018

Children with Low Vision Receive Unique Care at Hadassah

“The vision of world-renowned Prof. Isaac Caesar Michaelson, former Director of the Hadassah Medical Organization’s Department of Ophthalmology, of creating in 1973 The Jerusalem Institute for the Prevention of Blindness still amazes me,” says Dr. Claudia Yahalom, current head of the renamed Michaelson Institute for Rehabilitation of Vision at Hadassah Hospital Ein Kerem.

READ MORE ›
alt_text

Tuesday, Nov 6 2018

Hadassah Staff Saves Seven-Year-Old From Deadly Scorpion Bite

The intensity of his cry alerted Elisha Alush’s parents that something serious had happened to their seven-year-old. He ran in from the backyard of their home near Jericho, north of Jerusalem, screaming, “My foot, my foot.” And then he lost consciousness.

READ MORE ›
alt_text

Thursday, Nov 1 2018

Hadassah Saves Soccer Fan’s Life in Newly Inaugurated Heart Center

Mickey Peretz, age 36, began his evening at a Beitar Jerusalem soccer game. Little did he know that he would end the evening being the first patient to receive a life-saving heart catheterization in Hadassah Hospital Ein Kerem’s brand new Irma and Paul Milstein Heart Center.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More